Select country change
Shopping cart (0 , 0,00 ) Menu Search
Manufactured by BioVendor

hsa-miR-423-5p miREIA

  • Regulatory status:RUO
  • Type:miREIA – miRNA enzyme immunoassay
  • Species:Human
Please select your region to see available products and prices.
Cat. No. Size Price


New RDM0033H 96 wells (1 kit)
PubMed Product Details
Technical Data

Type

miREIA – miRNA enzyme immunoassay

Applications

Whole blood, PBMC, Cell culture lysates

Sample Requirements

10 µl/well

Shipping

At ambient temperature. Upon receipt, store the product at the temperature recommended below.

Storage/Expiration

Store the complete kit at 2 – 8 °C. Under these conditions, all components are stable until the expiration date (see label on the box).

Calibration Curve

Calibration Range

12.5 – 0.39 amol/μl

Limit of Detection

0.13 amol/μl

Intra-assay (Within-Run)

n = 8,
CV = 10.1%

Inter-assay (Run-to-Run)

n = 5,
CV = 8.5%

Spiking Recovery

103.6%

Dilution Linearity

94.1%

Summary

Features

  • It is intended for research use only
  • The total assay time is less than 2.5 hours
  • The kit measures hsa-miR-423-5p isolated from human blood
  • Assay format is 96 wells
  • Standard is synthetic miRNA-based
  • Components of the kit are provided ready to use, concentrated or dried

Research topic

Cardiovascular disease, Diabetology - Other Relevant Products, Oncology, Pulmonary diseases

Summary

MicroRNAs (miRNAs) are small non-coding RNA molecules, approximately 22 nucleotides in length that regulate gene translation through silencing or degradation of target mRNAs. They are involved in multiple biological processes, including differentiation and proliferation, metabolism, hemostasis, apoptosis or inflammation, and in pathophysiology of many diseases. Numerous studies have suggested circulating miRNAs as promising diagnostic and prognostic biomarkers of many diseases.

MiR-423-5p is located within the first intron of nuclear speckle splicing regulatory protein 1 gene (NSRP1) on chromosome 17 and has been reported as an oncogenic factor in many cancers including glioblastoma, gastric cancer and prostate cancer. In contrast, miR-423-5p functions as a tumor suppressor and may serve as a diagnostic indicator in ovarian cancer and osteosarcoma.

MiR-423-5p was originally identified as a circulating biomarker for heart disease. Tijsen et al. demonstrated that circulating levels of miR-423-5p were increased in patients with clinical heart failure. Other studies suggest that miR-423-5p is enriched in pericardial fluid, and serum miR-423-5p may be associated with unstable angina pectoris. Furthermore, cellular miR-423-5p may discriminate stable coronary artery disease (CAD) patients from unstable CAD patients at six months post- acute myocardial infarction.

Additionally, it was demonstrated that miR-423–5p expression was markedly increased in blood plasma of pregnant women with preeclampsia compared with healthy control group. Moreover, miR-423-5p is also involved in hepatic glucose and lipid metabolism. Hepatic miR-423-5p inhibition suppressed gluconeogenesis and improved insulin resistance, hyperglycemia, and fatty liver in obese diabetic mice. Lastly, miR-423-5p has been reported as a reliable diagnostic biomarker for active tuberculosis.

Summary References (11)

References to miR-423-5p

  • Rizzacasa, Barbara, et al. "MiR-423 is differentially expressed in patients with stable and unstable coronary artery disease: A pilot study." PloS one 14.5 (2019): e0216363.
  • Li, Shouwei, et al. "miR-423-5p contributes to a malignant phenotype and temozolomide chemoresistance in glioblastomas." Neuro-oncology 19.1 (2016): 55-65.
  • Liu, Jingjing, et al. "miRNA423-5p regulates cell proliferation and invasion by targeting trefoil factor 1 in gastric cancer cells." Cancer letters 347.1 (2014): 98-104.
  • Lin, Haili, et al. "Inhibition of miR-423-5p suppressed prostate cancer through targeting GRIM-19." Gene 688 (2019): 93-97.
  • Tang, Xuebiao, et al. "miR 423 5p serves as a diagnostic indicator and inhibits the proliferation and invasion of ovarian cancer." Experimental and therapeutic medicine 15.6 (2018): 4723-4730.
  • Wang, Xuesong, et al. "miR-423-5p inhibits osteosarcoma proliferation and invasion through directly targeting STMN1." Cellular Physiology and Biochemistry 50.6 (2018): 2249-2259.
  • Tijsen, Anke J., et al. "MiR423-5p as a circulating biomarker for heart failure." Circulation research 106.6 (2010): 1035.
  • Miyamoto, Shoichi, et al. "Expression patterns of miRNA-423-5p in the serum and pericardial fluid in patients undergoing cardiac surgery." PloS one 10.11 (2015): e0142904.
  • Guo, Li, et al. "MicroRNA-423–5p inhibits the progression of trophoblast cells via targeting IGF2BP1." Placenta 74 (2018): 1-8.
  • Yang, Weili, et al. "NFE2 induces miR-423-5p to promote gluconeogenesis and hyperglycemia by repressing the hepatic FAM3A-ATP-Akt pathway." Diabetes 66.7 (2017): 1819-1832.
  • Tu, Huihui, et al. "Elevated pulmonary tuberculosis biomarker miR-423-5p plays critical role in the occurrence of active TB by inhibiting autophagosome-lysosome fusion." Emerging microbes & infections 8.1 (2019): 448-460.
Related Products Docs